Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.86 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.82 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3073695 | 0.99 | S1PR1 (0.85) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3076256 | 0.96 | S1PR1 (0.88) | S1PR1S1PR5S1PR3 | |
| Hydrochloric Acid SCHEMBL3063115 | 0.95 | S1PR1 (0.86) | S1PR1S1PR5S1PR3 | |
| SCHEMBL12852172 | 0.93 | S1PR1 (0.79) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2602116 | 0.92 | S1PR1 (1.00) | S1PR1S1PR5S1PR3 | |
| Hydrochloric Acid SCHEMBL3068164 | 0.92 | S1PR1 (0.98) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2602060 | 0.90 | S1PR1 (1.00) | S1PR1S1PR5S1PR3 | |
| Formic Acid SCHEMBL3062406 | 0.90 | S1PR1 (0.75) | S1PR1S1PR5S1PR3 | |
| Formic Acid SCHEMBL3660538 | 0.90 | S1PR1 (0.94) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2123242 | 0.90 | S1PR1 (0.99) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225233-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | Glaxo Group Limited (GB) | 2010-09-08 | — | — | EP | claimed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | claimed |
| EP-2746254-A2 | Oxadiazole derivative active on sphingosine-1-phosphate (s1p) | Glaxo Group Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| US-8278324-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2225233-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | Glaxo Group Limited (GB) | 2010-09-08 | — | — | EP | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR5 5/4885S1PR3 1/4885 |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR5 5/4885S1PR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.